Akari Therapeutics (ADR) (AKTX)
Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.
Something off on this page? Send us feedback.
Develops a preclinical oncology ADC platform and anti-cancer candidates using novel payloads; AKTX-101 pairs a TROP2 target with PH1. The development-stage business focuses on research, development, and capital raising.
Following the Peak Bio acquisition, substantially all work has centered on a preclinical oncology antibody-drug-conjugate platform and anti-cancer candidates with novel payloads applied to clinically validated targets. AKTX-101, the lead program, pairs a TROP2 target with its PH1 payload.
The present legal entity was established in England in 2004 and maintains its principal US office in Tampa, Florida; its ADSs trade on Nasdaq. The development-stage business has conducted research, development, and capital-raising activities since inception.
Development of the platform and pipeline depends on additional capital. The current operating frame was shaped by the Peak Bio transaction.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 16, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $19.50 |
| Jul 20, 2026 | Maxim Group | Upgrade | Target: — | Target: $30 |
| Apr 8, 2026 | Maxim Group | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.7M · Total debt $693.0K · Total assets $38.6M · Shareholders' equity $18.6M
- Revenue
- $0
- Operating income
- −$4.6M
- Net income
- −$4.8M
No dividends on record.
| Institutions | 13.10% | 150.0K ADS | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Insiders | 2.13% | 24.4K ADS | |
| 2 holders · as of Aug 19, 2026 | |||
| Other | 84.77% | 970.2K ADS | |
| remainder | |||
1.14M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mmcap International Inc. SPCInstitution | 8.74% | 100,000 ADS | as of Jun 30, 2026 |
Kameel D. FaragInsiderofficer: Interim CFO | 2.04% | 23,309 ADS | filed Aug 19, 2026 |
Cresset Asset Management, LLCInstitution | 1.80% | 20,561 ADS | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 1.35% | 15,463 ADS | as of Jun 30, 2026 |
HRT Financial LPInstitution | 1.20% | 13,745 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 16, 2025 | James R. Neal | director | +11,132 | $0.3883 |
| Dec 16, 2025 | Robert B. Bazemore | director | +309,326 | $0.3883 |
| Dec 16, 2025 | Abizer Gaslightwala | director, officer: CEO | +2,165,302 | $0.3883 |
| Dec 16, 2025 | Samir Rashmikant Patel | director, 10 percent owner: | +1,701,310 | $0.3883 |
| Dec 16, 2025 | Kameel D. Farag | officer: Interim CFO | +49,490 | $0.3883 |
- Gilead Sciences
Approved TROP2 ADC for breast cancer with an SN-38 payload
- Merck
Global Phase 3 TROP2 ADC development with sacituzumab tirumotecan
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Akari Therapeutics (ADR) | $10.42 | +3.68% | $11.5M | — | — | — | — |
| Gilead Sciences | $150.57 | −1.38% | $189.30B | — | 16.6 | 6.2 | +10.2% |
| Merck | $146.99 | −2.60% | $372.73B | 120.7 | 17.0 | 5.6 | +5.1% |
| Median | 120.7 | 16.8 | 5.9 | +7.6% |